Canaccord raised the firm’s price target on Penumbra (PEN) to $359 from $355 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra: Top Pick for 2026 with Strong Growth Catalysts and Margin Improvements
- Penumbra price target raised to $345 from $310 at Baird
- Penumbra upgraded to Buy from Neutral at Citi
- Penumbra’s Promising Growth: Buy Rating Backed by Strong Portfolio and Technological Advancements
- Penumbra’s Promising Growth: Buy Rating Backed by STORM-PE Trial and Market Expansion